Dr. Reddy's Laboratories/$RDY
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Dr. Reddy's Laboratories
Dr. Reddy's is one of the largest generic drug manufacturers in the world. It has a significant presence in North America, a region that makes up roughly 40% of its generics sales, with other key markets being India (20%) and Europe (20%). Beyond simple generics, Dr. Reddy's also has a solid portfolio of injectables which make up 25% of its North America sales. In branded generic markets like India, Dr. Reddy's has established a compelling presence with its strong brand name and earned a top five spot in key therapeutic areas including oncology and gastroenterology. Dr. Reddy's also has an active pharmaceutical ingredient business that manufactures over 150 APIs and sells in over 75 countries.
Ticker
$RDY
Sector
Primary listing
NYSE
Employees
27,527
Headquarters
Hyderabad, India
Website
RDY Metrics
BasicAdvanced
$11bn
24.77
$0.54
0.26
$0.07
0.54%
Price and volume
Market cap
$11bn
Beta
0.26
52-week high
$16.17
52-week low
$12.19
Average daily volume
2.3m
Dividend rate
$0.07
Financial strength
Current ratio
1.802
Quick ratio
1.131
Long term debt to equity
3.207
Total debt to equity
20.328
Dividend payout ratio (TTM)
15.54%
Interest coverage (TTM)
13.17%
Profitability
EBITDA (TTM)
714.883
Gross margin (TTM)
52.77%
Net profit margin (TTM)
12.76%
Operating margin (TTM)
14.86%
Effective tax rate (TTM)
22.53%
Revenue per employee (TTM)
$127,970
Management effectiveness
Return on assets (TTM)
5.82%
Return on equity (TTM)
11.84%
Valuation
Price to earnings (TTM)
24.768
Price to revenue (TTM)
3.156
Price to book
2.82
Price to tangible book (TTM)
4.1
Price to free cash flow (TTM)
53.732
Free cash flow yield (TTM)
1.86%
Free cash flow per share (TTM)
0.249
Dividend yield (TTM)
0.54%
Forward dividend yield
0.54%
Growth
Revenue change (TTM)
3.19%
Earnings per share change (TTM)
-24.14%
3-year revenue growth (CAGR)
10.96%
10-year revenue growth (CAGR)
8.12%
3-year earnings per share growth (CAGR)
-1.72%
10-year earnings per share growth (CAGR)
8.19%
10-year dividend per share growth (CAGR)
7.18%
What the Analysts think about RDY
Analyst ratings (Buy, Hold, Sell) for Dr. Reddy's Laboratories stock.
RDY Financial Performance
Revenues and expenses
RDY Earnings Performance
Company profitability
RDY News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
FAQs